Accustem Sciences (ACUT) Assets Average (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Assets Average of $1.5 million for Q1 2026, up 93.51% year-over-year from $800717.5 in Q1 2025, and down 0.76% quarter-over-quarter from $1.6 million in Q4 2025.
Accustem Sciences (ACUT) Assets Average (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Assets Average for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 93.51% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 93.51% YoY), while the FY2025 annual figure was $800148.5, up 766.21% from the prior year.
- Assets Average fell to $1.5 million in Q1 2026 per ACUT's latest filing, from $1.6 million in the prior quarter.
- Across five years, Assets Average topped out at $2.8 million in Q2 2022 and bottomed at $77335.0 in Q4 2024.
- Historically, Assets Average has averaged $1.0 million across 5 years, with a median of $800717.5 in 2025.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 87.47% — and 2025, when it jumped 1918.94%.
- Accustem Sciences' Assets Average stood at $1.3 million in 2022, then plunged by 84.72% to $195736.0 in 2023, then slumped by 60.49% to $77335.0 in 2024, then surged by 1918.94% to $1.6 million in 2025, then dropped by 0.76% to $1.5 million in 2026.
- Business Quant data shows ACUT's Assets Average at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 800,717.50 |
| Dec 31, 2024 | 77,335.00 |
| Sep 30, 2024 | 121,739.50 |
| Jun 30, 2024 | 95,300.50 |
| Mar 31, 2024 | 92,419.00 |
| Dec 31, 2023 | 195,736.00 |
| Sep 30, 2023 | 358,052.50 |
| Jun 30, 2023 | 353,044.50 |
| Mar 31, 2023 | 593,624.00 |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.82 Mn |
| Mar 31, 2022 | 2.30 Mn |